References
- Abramson J S. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist 2006; 11: 384–392
- Castella A, Joshi S, Raaschou T, Mason N. Pattern of malignant lymphoma in the United Arab Emirates—a histopathologic and immunologic study in 208 native patients. Acta Oncol 2001; 40: 660–664
- Baker H, Al-Jarallah M, Manguno H, Temmim L, Madda J P, Sinowatz F. Clinical characteristics and pathological classification of non-Hodgkin's lymphoma in Kuwait. Results of a collaborative study with the International Lymphoma Study Group (ILSG). Leuk Lymphoma 2004; 45: 1865–1871
- Koriech O M, Al-Kuhaymi R. Profile of cancer in Riyadh Armed Forces Hospital. Ann Saudi Med 1994; 14: 187–194
- Haddadin W J. Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med 2005; 25: 398–403
- Monti S, Savage K J, Kutok J L, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar R C, Dal Cin P, Ladd C, Pinkus G S, Salles G, Harris N L, Dalla-Favera R, Habermann T M, Aster J C, Golub T R, Shipp M A. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861
- Takahashi H, Feuerhake F, Kutok J L, Monti S, Dal Cin P, Neuberg D, Aster J C, Shipp M A. FAS death domain deletions and cellular FADD-like interleukin 1β converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res 2006; 12: 3265–3271
- Abramson J S, Shipp M A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164–1174
- Feuerhake F, Kutok J L, Monti S, Chen W, Lacasce A S, Cattoretti G, Kurtin P, Pinkus G S, de Leval L, Harris N L, Savage K J, Neuberg D, Habermann T M, Dalla-Favera R, Golub T R, Aster J C, Shipp M A. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399
- Kitada S, Zapata J M, Andreeff M, Reed J C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995–1004
- Dunn G P, Old L J, Schreiber R D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137–148
- Yang Z Z, Novak A J, Stenson M J, Witzig T E, Ansell S M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639–3646